PMVP — Pmv Pharmaceuticals Share News
0.000.00%
Last trade - 00:00Brief: PMV Pharma Reports FY22 Financial Results And Corporate Highlights
PMV Pharmaceuticals Inc expected to post a loss of 44 cents a share - Earnings Preview
PMV Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Pmv Pharmaceuticals Reports Third Quarter Results
PMV Pharmaceuticals Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: PMV Pharmaceuticals Appoints Industry Veteran Carol Gallagher To Board Of Directors
PMV Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary
Brief: PMV Pharmaceuticals Inc Reports Second Quarter 2022 Financial Results
PMV Pharmaceuticals Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: Pmv Pharmaceuticals Announces Clinical Trial Collaboration With Merck To Evaluate PC14586 In Combination With Keytruda In Patients With Advanced Solid Tumors
NASDAQ RESUMED AT 12:39 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:34 PM
NASDAQ RESUMED AT 12:32 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:27 PM
NASDAQ RESUMED AT 12:11 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:06 PM
NASDAQ RESUMED AT 12:05 PM
Brief: Pmv Pharmaceuticals Initial Pc14586 Phase 1 Data Presented At Asco Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With A P53 Y220c Mutation
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:00 PM